PS 1145 dihydrochlorideSelective IKK inhibitor; orally active CAS# 1049743-58-9 |
2D Structure
- Piceatannol
Catalog No.:BCN5824
CAS No.:10083-24-6
- R788 disodium
Catalog No.:BCC3695
CAS No.:1025687-58-4
- GS-9973
Catalog No.:BCC5278
CAS No.:1229208-44-9
- R406 (free base)
Catalog No.:BCC2553
CAS No.:841290-80-0
- Fostamatinib (R788)
Catalog No.:BCC5082
CAS No.:901119-35-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1049743-58-9 | SDF | Download SDF |
PubChem ID | 16219884 | Appearance | Powder |
Formula | C17H13Cl3N4O | M.Wt | 395.67 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 5 mM in DMSO with gentle warming | ||
Chemical Name | N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)pyridine-3-carboxamide;dihydrochloride | ||
SMILES | C1=CC(=CN=C1)C(=O)NC2=C3C(=CC(=C2)Cl)C4=C(N3)C=NC=C4.Cl.Cl | ||
Standard InChIKey | QTDCBADLGJZBHP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H11ClN4O.2ClH/c18-11-6-13-12-3-5-20-9-15(12)21-16(13)14(7-11)22-17(23)10-2-1-4-19-8-10;;/h1-9,21H,(H,22,23);2*1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective IκB kinase (IKK) inhibitor (IC50 = 100 nM). Has no effect on PKA, PKC and CKII activity. Inhibits IκB-α phosphorylation and NFκB activation in HeLa cells. Inhibits NFκB-mediated proinflammatory gene expression in human airway epithelial cells. Enhances TNF-α-induced apoptosis in a multiple myeloma cell line. Attenuates LPS-induced TNF-α production in vivo. Orally active. |
PS 1145 dihydrochloride Dilution Calculator
PS 1145 dihydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5274 mL | 12.6368 mL | 25.2736 mL | 50.5472 mL | 63.184 mL |
5 mM | 0.5055 mL | 2.5274 mL | 5.0547 mL | 10.1094 mL | 12.6368 mL |
10 mM | 0.2527 mL | 1.2637 mL | 2.5274 mL | 5.0547 mL | 6.3184 mL |
50 mM | 0.0505 mL | 0.2527 mL | 0.5055 mL | 1.0109 mL | 1.2637 mL |
100 mM | 0.0253 mL | 0.1264 mL | 0.2527 mL | 0.5055 mL | 0.6318 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cardiogenol C hydrochloride
Catalog No.:BCC7790
CAS No.:1049741-55-0
- A 331440 dihydrochloride
Catalog No.:BCC7963
CAS No.:1049740-32-0
- Naspm trihydrochloride
Catalog No.:BCC7476
CAS No.:1049731-36-3
- 8-Hydroxydigitoxigenin
Catalog No.:BCN5864
CAS No.:1049674-06-7
- Ethyl β-D-ribo-hex-3-ulopyranoside
Catalog No.:BCC8977
CAS No.:104953-08-4
- H-D-Val-OtBu.HCl
Catalog No.:BCC3146
CAS No.:104944-18-5
- Tranilast Sodium
Catalog No.:BCC4091
CAS No.:104931-56-8
- Borapetoside B
Catalog No.:BCN6593
CAS No.:104901-05-5
- dl-Aloesol
Catalog No.:BCN7265
CAS No.:104871-04-7
- (+)-Isopulegol
Catalog No.:BCN4975
CAS No.:104870-56-6
- NF 023
Catalog No.:BCC6985
CAS No.:104869-31-0
- NF 157
Catalog No.:BCC7367
CAS No.:104869-26-3
- 3-Acetoxy-4,7(11)-cadinadien-8-one
Catalog No.:BCN5865
CAS No.:104975-02-2
- Tacrolimus (FK506)
Catalog No.:BCC4952
CAS No.:104987-11-3
- Ascomycin(FK 520)
Catalog No.:BCC1370
CAS No.:104987-12-4
- Pallidol
Catalog No.:BCN3306
CAS No.:105037-88-5
- AST-1306 TsOH
Catalog No.:BCC4043
CAS No.:1050500-29-2
- GPR120 modulator 1
Catalog No.:BCC1599
CAS No.:1050506-75-6
- GPR120 modulator 2
Catalog No.:BCC1600
CAS No.:1050506-87-0
- 1-Ketoaethiopinone
Catalog No.:BCN3219
CAS No.:105062-36-0
- Ro 51
Catalog No.:BCC6157
CAS No.:1050670-85-3
- Moellendorffilin
Catalog No.:BCN3546
CAS No.:105099-87-4
- Ligucyperonol
Catalog No.:BCN6638
CAS No.:105108-20-1
- GSK744 (S/GSK1265744)
Catalog No.:BCC3888
CAS No.:1051375-10-0
Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.[Pubmed:17322026]
J Pharmacol Exp Ther. 2007 May;321(2):734-42.
The airway epithelium is critical in the pathogenesis of chronic inflammatory diseases, such as asthma and chronic obstructive pulmonary disease, and, by expressing numerous inflammatory genes, plays a prominent role in disease exacerbations. Since inflammatory gene expression often involves the transcription factor nuclear factor (NF)-kappaB, this signaling pathway represents a site for anti-inflammatory intervention. As the airway epithelium is targeted by inhaled therapeutic agents, for example corticosteroids, human A549 pulmonary cells and primary human bronchial epithelial (HBE) cells were selected to evaluate inhibitor of kappaB kinase (IKK) inhibitors. In A549 cells, interleukin (IL)-1beta and tumor necrosis factor (TNF) alpha increased phosphorylation of IkappaBalpha, and this was followed by loss of IkappaBalpha, induction of NF-kappaB DNA binding, and the induction of NF-kappaB-dependent transcription. These events were repressed by the IKK-selective inhibitors, PS-1145 [N-(6-chloro-9H-beta-carbolin-8-ly) nicotinamide] and ML120B [N-(6-chloro-7-methoxy-9H-beta-carbolin-8-yl)-2-methyl-nicotinamide]. Inhibition of NF-kappaB-dependent transcription was concentration-dependent and correlated with loss of intercellular adhesion molecule (ICAM)-1 expression. Similarly, IL-1beta- and TNFalpha-induced expression of IL-6, IL-8, granulocyte macrophage-colony-stimulating factor (GM-CSF), regulated and activation normal T cell expressed and secreted (RANTES), growth-related oncogene alpha, and monocyte chemotactic protein-1 (MCP-1) was also significantly repressed. Likewise, PS-1145 and ML120B profoundly reduced NF-kappaB-dependent transcription induced by IL-1beta and TNFalpha in primary HBE cells. Parallel effects on ICAM-1 expression and a significant repression of IL-8 release were observed. In contrast, the corticosteroid, dexamethasone, was without effect on NF-kappaB-dependent transcription or the expression of ICAM-1. The above data provide strong support for an anti-inflammatory effect of IKK2 inhibitors acting on the pulmonary epithelium and suggest that such compounds may prove beneficial in situations where traditional corticosteroid therapies prove inadequate.
Novel IKK inhibitors: beta-carbolines.[Pubmed:12824047]
Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
Inhibitors of IkappaB kinase (IKK) have long been sought as specific regulators of NF-kappaB. A screening effort of the endogenous IKK complex allowed us to identify 5-bromo-6-methoxy-beta-carboline as a nonspecific IKK inhibitor. Optimization of this beta-carboline natural product derivative resulted in a novel class of selective IKK inhibitors with IC(50)s in the nanomolar range. In addition, we show that one of these beta-carboline analogues inhibits the phosphorylation of IkappaBalpha and subsequent activation of NF-kappaB in whole cells, as well as blocking TNF-alpha release in LPS-challenged mice.
NF-kappa B as a therapeutic target in multiple myeloma.[Pubmed:11872748]
J Biol Chem. 2002 May 10;277(19):16639-47.
We have shown that thalidomide (Thal) and its immunomodulatory derivatives (IMiDs), proteasome inhibitor PS-341, and As(2)O(3) act directly on multiple myeloma (MM) cells and in the bone marrow (BM) milieu to overcome drug resistance. Although Thal/IMiDs, PS-341, and As(2)O(3) inhibit nuclear factor (NF)-kappaB activation, they also have multiple and varied other actions. In this study, we therefore specifically address the role of NF-kappaB blockade in mediating anti-MM activity. To characterize the effect of specific NF-kappaB blockade on MM cell growth and survival in vitro, we used an IkappaB kinase (IKK) inhibitor (PS-1145). Our studies demonstrate that PS-1145 and PS-341 block TNFalpha-induced NF-kappaB activation in a dose- and time-dependent fashion in MM cells through inhibition of IkappaBalpha phosphorylation and degradation of IkappaBalpha, respectively. Dexamethasone (Dex), which up-regulates IkappaBalpha protein, enhances blockade of NF-kappaB activation by PS-1145. Moreover, PS-1145 blocks the protective effect of IL-6 against Dex-induced apotosis. TNFalpha-induced intracellular adhesion molecule (ICAM)-1 expression on both RPMI8226 and MM.1S cells is also inhibited by PS-1145. Moreover, PS-1145 inhibits both IL-6 secretion from BMSCs triggered by MM cell adhesion and proliferation of MM cells adherent to BMSCs. However, in contrast to PS-341, PS-1145 only partially (20-50%) inhibits MM cell proliferation, suggesting that NF-kappaB blockade cannot account for all of the anti-MM activity of PS-341. Importantly, however, TNFalpha induces MM cell toxicity in the presence of PS-1145. These studies demonstrate that specific targeting of NF-kappaB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu. Furthermore, they provide the framework for clinical evaluation of novel MM therapies based upon targeting NF-kappaB.